Has erdafitinib been marketed in the country and included in medical insurance?

Erdafitinib (Erdafitinib), as an innovative targeted drug, is specially used to treat specific types of advanced or metastatic urothelial cancer. This cancer originates from malignant tumors of the urinary system and involves multiple sites such as the bladder, renal pelvis, and ureters. For those patients whose condition continues to worsen despite chemotherapy, erdafitinib brings a new hope for treatment.

At present, erdafitinib has not officially entered the domestic market. Therefore, patients cannot directly purchase this drug in China for the time being and need to obtain it from overseas through other channels. If patients want to buy original drugs, they can choose the Hong Kong version, but its price is as high as more than 20,000 yuan and needs to be purchased through specific pharmacies in Hong Kong. In addition, overseas generic drugs provide more economical options, such as generic drugs from Laos and Bangladesh, with prices ranging from a few hundred yuan to more than 2,000 yuan, and the ingredients of these drugs are basically similar to the original drugs.

Erdafitinib is one of the multi-kinase inhibitors. Its main mechanism of action is to fight cancer by inhibiting multiple key kinases in tumors. Especially for FGFR (fibroblast growth factor receptor) kinase, which appears to be extremely active in a variety of cancers and promotes tumor growth. Through the inhibitory effect of erdafitinib, it can interfere with the proliferation of cancer cells, thereby curbing the further progression of cancer.

After clinical trials, erdafitinib has achieved significant results in the treatment of advanced urothelial cancer. Some patients who received erdafitinib showed that their tumors tended to shrink or that their disease was stably controlled. This is undoubtedly an important advance for patients who have experienced multiple treatments but failed to achieve results.

However, any medication can cause side effects. Common side effects of erdafitinib include fatigue, nausea, vomiting, diarrhea, etc., and skin rash and other reactions may also occur. In addition, due to the mechanism of action of the drug, patients may also suffer from more serious adverse reactions such as hypertension, visual impairment, and abnormal liver function. Therefore, before initiating treatment with erdafitinib, physicians will thoroughly evaluate the patient's physical condition and closely monitor the patient's response during treatment.